Novel CD123×CD33 bicistronic chimeric antigen receptor (CAR)-T therapy has potential to reduce escape from single-target CAR-T with no more hematotoxicity.
作者信息
Wang Zhenzhen, Lu Yang, Liu Yu, Mou Junli, Liu Xiaoyu, Chen Manling, Wang Ying, Xu Yingxi, Rao Qing, Xing Haiyan, Tang Kejing, Tian Zheng, Wang Bing, Qi Wei, Wang Min, Qiu Shaowei, Xiong Dongsheng, Wang Jianxiang
机构信息
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, P. R. China.
Novogene Co, Ltd, Beijing, P. R. China.
出版信息
Cancer Commun (Lond). 2023 Oct;43(10):1178-1182. doi: 10.1002/cac2.12474. Epub 2023 Jul 31.
Abstract
摘要
Zotero 插件